Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2011, Article ID 616080, 3 pages
http://dx.doi.org/10.1155/2011/616080
Case Report

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

1Division of Hematology, Oncology, Department of Medicine, Columbia University, NY 10027, USA
2Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
3Oncology Unit, 3rd Department of Medicine, Athens University School of Medicine, Building Z, Sotiria General Hospital, Mesogion 152, 115 27 Athens, Greece

Received 24 January 2011; Revised 28 March 2011; Accepted 7 April 2011

Academic Editor: Fabio Farinati

Copyright © 2011 Muhammad W. Saif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Wilhelm, C. Carter, L. Tang et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Porta, C. Paglino, I. Imarisio, and E. Ferraris, “Sorafenib tosylate in advanced kidney cancer: past, present and future,” Anti-Cancer Drugs, vol. 20, no. 6, pp. 409–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. W. Saif, “Platelet count less than SHARP: what does a case series reveal?” Expert Opinion on Drug Safety, vol. 9, no. 1, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. F. A. Scappaticci, J. R. Skillings, S. N. Holden et al., “Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab,” Journal of the National Cancer Institute, vol. 99, no. 16, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. T. K. Choueiri, F. A. Schutz, Y. Je, J. E. Rosenberg, and J. Bellmunt, “Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2280–2285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kamba and D. M. McDonald, “Mechanisms of adverse effects of anti-VEGF therapy for cancer,” British Journal of Cancer, vol. 96, no. 12, pp. 1788–1795, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. EMEA, “Nexavar, Scientific Discussion,” 2007, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000690/WC500027710.pdf.
  9. J. M. Katz and A. Z. Segal, “Incidence and etiology of cerebrovascular disease in patients with malignancy,” Current Atherosclerosis Reports, vol. 7, no. 4, pp. 280–288, 2005. View at Google Scholar · View at Scopus
  10. V. Ozenne, V. Paradis, S. Pernot et al., “Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib,” European Journal of Gastroenterology and Hepatolog, vol. 147, no. 1, pp. e1–e12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Meyer, L. Robles-Carrillo, T. Robson et al., “Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice,” Journal of Thrombosis and Haemostasis, vol. 7, no. 1, pp. 171–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Wu, J. J. Chen, A. Kudelka, J. Lu, and X. Zhu, “Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis,” The Lancet Oncology, vol. 9, no. 2, pp. 117–123, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Agnelli, G. Gussoni, C. Bianchini et al., “Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study,” The Lancet Oncology, vol. 10, no. 10, pp. 943–949, 2009. View at Publisher · View at Google Scholar · View at Scopus